The Psoriasis Drugs Market: 2020 – 2030 – Opportunities, Challenges, Strategies & Forecasts​


Release Date: May 2020
Number of Pages: 241
Number of Tables and Figures: 51
​
Synopsis: A chronic inflammatory disorder of the skin, psoriasis impacts over 125 million people worldwide and nearly 7.5 million in the United States. The main symptoms are thick visibly reddened scaly patches of skin which cause itching and pain. Although psoriasis is not a life-threatening disease, it is associated with significant physical, psychosocial, and economic burdens corresponding to disease severity.  With the rising awareness and expectations about skin, hair, and nail appearance, there is an increase in patients exploring more effective treatment options for psoriasis. 
​
The need for treatment is lifelong, aimed at remission by preventing skin cells from growing rapidly and reducing inflammation. Treatment is determined by the type, area of skin affected and severity of psoriasis in a patient. Mild psoriasis can largely be treated with topical therapies, while moderate-to-severe psoriasis is treated with oral systemics, biologics or a combination therapy. Over the last decade several new psoriasis therapies have materialized, propelled by development of targeted biologics including tumor necrosis factor (TNF), interleukin (IL)-12/23 and IL-17 inhibitors.
SNS Research estimates that the psoriasis drugs market will account for nearly $11.5 Billion in revenue by the end of 2020. Despite challenges relating to drug stability, and patent disputes amongst competition, the market is poised for significant growth over the forecast period, with several novel drugs in late-stage development.

The “Psoriasis Drugs Market: 2020 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the psoriasis drugs ecosystem including psoriasis disorders, types of treatment options, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for psoriasis drugs from 2020 through to 2030. The forecasts are segmented for over 4 therapeutic classes, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report, as well as an Excel sheet covering clinical drug development pipeline for the psoriasis market, profiling 76 future candidates.

For a Sample and Table of Contents please contact [email protected]

Pricing: The report is available for the following price: 
​
Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:​
  • Expected to reach nearly $11.5 Billion in global spending by the end of 2020, with a high prevalence of psoriasis in the population and the chronic nature of the disease, psoriasis treatment options are expected to see a stable growth throughout the forecast period. 
  • Biologics are continuing to retain their strong foothold in the psoriasis market with a number of recent approvals such as Cimzia (Certolizumab pegol), Ilumya (tildrakizumab-asmn), and Skyrizi (Risankizumab), however patent litigation lawsuits have delayed the launch of several FDA approved biosimilars in the US market, posing a barrier to availability of low cost treatment options.  
  • New drug development programs for psoriasis are largely based on TNF-alpha inhibitors and selective inhibition of interleukins including IL-12, IL-17, and IL-23. 
  • Other programs include but are not limited to PD-L1 (Programmed Death Ligand-1) antibodies; topical treatments such as JAK (Janus Kinase) inhibitors, TYIs (Tyrosine Kinase Inhibitors) and PDE-4 (Phosphodiesterase-4) inhibitors; VDR (Vitamin D Receptors); and new combination therapies. 
  • The market is continuing to consolidate with several prominent acquisitions and partnerships such as the recent acquisition of U.S. based Celgene by Bristol-Myers Squibb for $74 billion. 

Topics Covered:
The report covers the following topics:
  • Psoriasis drugs ecosystem 
  • Market drivers and barriers 
  • Psoriasis disorders and key trends 
  • Analysis of key drug classes and leading psoriasis drugs 
  • Future drug development pipeline 
  • Psoriasis drug delivery technologies 
  • Industry roadmap and value chain 
  • Profiles and strategies of 88 leading ecosystem players, including psoriasis drug developers 
  • Strategic recommendations for ecosystem players 
  • Market analysis and forecasts from 2020 till 2030 

Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Therapeutic Class
    • ​TNF Inhibitors 
    • Interleukins 
    • Vitamin D Analogues & Topical Steroids 
    • Others 
  • Regional Markets
    • ​Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • ​Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the psoriasis drugs opportunity? 
  • What trends, challenges and barriers are influencing its growth? 
  • How is the ecosystem evolving by segment and region? 
  • What will the market size be in 2025 and at what rate will it grow? 
  • Which countries and submarkets will see the highest percentage of growth? 
  • What are the prospects of biosimilar drugs in psoriasis? 
  • How big is the market for psoriasis drugs? 
  • Who are the key market players and what are their strategies? 
  • How will patent expirations of innovator drugs impact the market? 
  • What strategies should psoriasis drug manufacturers adopt to remain competitive?  

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
23andMe
Abbott Laboratories
AbbVie
AbGenomics
Aclaris Therapeutics
Affibody
Akros Pharma (Japan Tobacco)
Alder BioPharmaceuticals
Allergan
Almirall
Alvotech
Amgen
AnaptysBio
Aralez Pharmaceuticals
Arcutis
AstraZeneca
Azitra
Bayer Pharmaceuticals
Beijing Wenfeng Tianji Pharmaceuticals
Biocad
Biocon
Biofrontera
Biogen
BioMimetix
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Boston Pharmaceuticals
Botanix Pharmaceuticals
Cadila Pharmaceuticals
Can-Fite BioPharma
Celgene Corporation
Celltrion Healthcare
Cipher Pharmaceuticals
Coherus BioScience
Creabilis SA
Cumberland Pharmaceuticals
Cutanea
Dermavant Sciences
Dr Reddys Laboratories
EC (European Commission)
Eli Lilly and Company
EMA (European Medicines Agency)
Encore Dermatology
EPI Health
Escalier Biosciences
Evelo Biosciences
Exicure
FDA (U.S. Food and Drug Administration)
Forward-Pharma
Galapagos
Galderma
Galectin Therapeutics
Gilead Sciences
Glenmark Pharmaceuticals
GSK (GlaxoSmithKline)
Hanwha Chemical
Immune Pharmaceuticals
Incyte Corporation
Innovation Pharmaceuticals
Inventiva
Jiangsu Hengrui Medicine
Johnson & Johnson
JT (Japan Tobacco)
Kadmon Holdings
LEO Pharma
Lipidor
Lycera
Maruho Company
Mayne Pharma Group
MC2 Therapeutics
Merck
MorphoSys
Mylan
Novan
Novartis
Ortho Dermatologics (Bausch Health Companies)
Patagonia Pharmaceuticals
Pfizer
Photogen Technologies Inc.
Pierre Fabre (Laboratoires Pierre Fabre)
Pola Pharma (Sun Pharma)
Polichem (Almirall)
Portal Instruments
Principia Biopharma
Promius Pharma
Provectus Biopharmaceuticals
Purdue Pharma
Quotient Sciences
Reata Pharmaceuticals
Samsung Group
Samumed
Sandoz
Sanofi
Santalis Healthcare (TFS Corporation)
Sienna Biopharmaceuticals
Sun Pharmaceutical Industries
Theravance Biopharma
UCB
Vitaeris
Welichem Biotech
XBiotech
XenoPort
Ziarco
Zydus Group (Cadila Healthcare)